Prospects for gene therapy of osteopetrosis

Current Gene Therapy

Volumn 9, Issue 3, 2009, Pages 150-159

  Askmyr, Maria ^a   Flores, Carmen ^a   Fasth, Anders ^b   Richter, Johan ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Bone remodelling; Engraftment; Hematopoietic stem cell; Oc oc mouse; Osteoblast; Osteoclast; Stem cell transplantation; Viral vector

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CARBONATE DEHYDRATASE II; GENE PRODUCT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPETROSIS ASSOCIATED TRANSMEMBRANE PROTEIN 1; PLECKSTRIN HOMOLOGY DOMAIN CONTAINING FAMILY M 1; PROTEIN CLCN7; PROTEIN TCIRG1; PROTON PUMP; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE CELL; CELL FUNCTION; DRUG DETERMINATION; GENE MUTATION; GENETIC TRANSDUCTION; HUMAN; OSTEOCLAST; PHENOTYPE; PROMOTER REGION; REVIEW; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BONE REMODELING; DRUG EFFECT; GENE THERAPY; GENETICS; HEMATOPOIETIC STEM CELL; MOUSE; PATHOLOGY;

ANIMALIA;

ANIMALS; BONE REMODELING; GENE THERAPY; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; OSTEOCLASTS; OSTEOPETROSIS;

EID: 70349564800     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309788488613     Document Type: Review

References (89)

1. Schönberg A. Röntgenbilder einer seltenen Knockenerk-rankung. Munch Med Wochenschr 1904; 51: 365-8.
2. Van Wesenbeeck L, Van Hul W. Lessons from osteopetrotic mutations in animals: impact on our current understanding of osteoclast biology. Crit Rev Eukaryot Gene Expr 2005; 15: 133-62.
3. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 289: 1508-14.
4. Sims NA, Gooi JH. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008; 19: 444-51.
5. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008; 2: 313-9.
6. Li Z, Kong K, Qi W. Osteoclast and its roles in calcium metabolism and bone development and remodeling. Biochem Biophys Res Commun 2006; 343: 345-50.
7. Mizoguchi T, Muto A, Udagawa N, et al. Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. J Cell Biol 2009; 184, 541-54.
8. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol 2007; 170: 427-35.
9. McHugh KP, Hodivala-Dilke K, Zheng MH, et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000; 105: 433-40.
10. Stenbeck G. Formation and function of the ruffled border in osteoclasts. Semin Cell Dev Biol 2002; 13: 285-92.
11. Schlesinger PH, Blair HC, Teitelbaum SL, Edwards JC. Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J Biol Chem 1997; 272: 18636-43.
12. Mattsson JP, Schlesinger PH, Keeling DJ, et al. Isolation and reconstitution of a vacuolar-type proton pump of osteoclast membranes. J Biol Chem 1994; 269: 24979-82.
13. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989; 245: 855-7.
14. +)-ATPases - nature's most versatile proton pumps. Nat Rev Mol Cell Biol 2002; 3: 94-103.
15. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000; 113 (Pt 3): 377-81.
16. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998; 95: 13453-8.
17. Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999; 14: 1654-63.
18. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 1983; 80: 2752-6.
19. Sly WS, Sato S, Zhu XL. Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis. Clin Biochem 1991; 24: 311-8.
20. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med 2004; 351: 2839-49.
21. Van Wesenbeeck L, Odgren PR, Coxon FP, et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest 2007; 117: 919-30.
22. Del Fattore A, Fornari R, Van Wesenbeeck L, et al. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 ( PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J Bone Miner Res 2008; 23: 380-91.
23. Fasth A, Porras O. Human malignant osteopetrosis: pathophysiology, management and the role of bone marrow transplantation. Pediatr Transplant 1999; 3 (Suppl 1): 102-7.
24. Wilson CJ, Vellodi A. Autosomal recessive osteopetrosis: diagnosis, management, and outcome. Arch Dis Child 2000; 83: 449-52.
25. Marks SC, Jr., Seifert MF, Lane PW. Osteosclerosis, a recessive skeletal mutation on chromosome 19 in the mouse. J Hered 1985; 76: 171-6.
26. Scimeca JC, Franchi A, Trojani C, et al. The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 2000; 26: 207-13.
27. Li YP, Chen W, Liang Y, Li E, Stashenko P. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 1999; 23: 447-51.
28. Sobacchi C, Frattini A, Orchard P, et al. The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet 2001; 10: 1767-73.
29. Frattini A, Orchard PJ, Sobacchi C, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 2000; 25: 343-6.
30. Frattini A, Pangrazio A, Susani L, et al. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res 2003; 18: 1740-7.
31. Heinemann T, Bulwin GC, Randall J, et al. Genomic organization of the gene coding for TIRC7, a novel membrane protein essential for T cell activation. Genomics 1999; 57: 398-406.
32. +-ATPase subunit a. J Biol Chem 2001; 276: 40050-4.
33. +-ATPase a-subunit gene. J Biol Chem 2001; 276: 42382-8.
34. Smith AN, Skaug J, Choate KA, et al. Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing. Nat Genet 2000; 26: 71-5.
35. Manolson MF, Yu H, Chen W, et al. The a3 isoform of the 100-kDa V-ATPase subunit is highly but differentially expressed in large (>or=10 nuclei) and small (
36. Kornak U, Kasper D, Bosl MR, et al. Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001; 104: 205-15.
37. Kasper D, Planells-Cases R, Fuhrmann JC, et al. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 2005; 24: 1079-91.
38. Campos-Xavier AB, Saraiva JM, Ribeiro LM, Munnich A, Cormier-Daire V. Chloride channel 7 (CLCN7) gene mutations in intermediate autosomal recessive osteopetrosis. Hum Genet 2003; 112: 186-9.
39. Quarello P, Forni M, Barberis L, et al. Severe malignant osteopetrosis caused by a GL gene mutation. J Bone Miner Res 2004; 19: 1194-9.
40. Chalhoub N, Benachenhou N, Rajapurohitam V, et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med 2003; 9: 399-406.
41. Ramirez A, Faupel J, Goebel I, et al. Identification of a novel mutation in the coding region of the grey-lethal gene OSTM1 in human malignant infantile osteopetrosis. Hum Mutat 2004; 23: 471-6.
42. Rajapurohitam V, Chalhoub N, Benachenhou N, et al. The mouse osteopetrotic grey-lethal mutation induces a defect in osteoclast maturation/function. Bone 2001; 28: 513-23.
43. Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC. CIC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 2006; 440: 220-3.
44. Pata M, Heraud C, Vacher J. OSTM1 bone defect reveals an intercellular hematopoietic crosstalk. J Biol Chem 2008; 283: 30522-30.
45. Maranda B, Chabot G, Decarie JC, et al. Clinical and cellular manifestations of OSTM1-related infantile osteopetrosis. J Bone Miner Res 2008; 23: 296-300.
46. Cleiren E, Benichou O, Van Hul E, et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 2001; 10: 2861-7.
47. Waguespack SG, Hui SL, Dimeglio LA, Econs MJ. Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. J Clin Endocrinol Metab 2006; 92: 771-8.
48. Waguespack SG, Koller DL, White KE, et al. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 2003; 18: 1513-8.
49. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007; 39: 960-2.
50. Guerrini MM, Sobacchi C, Cassani B, et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008; 83: 64-76.
51. Coccia PF, Krivit W, Cervenka J, et al. Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med 1980; 302: 701-8.
52. Ballet JJ, Griscelli C, Coutris C, Milhaud G, Maroteaux P. Bone-marrow transplantation in osteopetrosis. Lancet 1977; 2: 1137.
53. Walker DG. Control of bone resorption by hematopoietic tissue. The induction and reversal of congenital osteopetrosis in mice through use of bone marrow and splenic transplants. J Exp Med 1975; 142: 651-63.
54. Walker DG. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 1975; 190: 784-5.
55. Gerritsen EJ, Vossen JM, Fasth A, et al. Bone marrow transplantation for autosomal recessive osteopetrosis. A report from the Working Party on Inborn Errors of the European Bone Marrow Transplantation Group. J Pediatr 1994; 125: 896-902.
56. Driessen GJ, Gerritsen EJ, Fischer A, et al. Long-term outcome of haematopoietic ste m cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplant 2003; 32: 657-63.
57. Frattini A, Blair HC, Sacco MG, et al. Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero. Proc Natl Acad Sci USA 2005; 102: 14629-34.
58. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 2007; 9: 833-42.
59. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-3.
60. Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Abina S, Fischer A. Gene therapy for severe combined immunodeficiency. Annu Rev Med 2005; 56: 585-602.
61. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-9.
62. Ott MG, Seger R, Stein S, et al. Advances in the treatment of Chronic Granulomatous Disease by gene therapy. Curr Gene Ther 2007; 7: 155-61.
63. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-6.
64. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-9.
65. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-58.
66. Cartier N, Aubourg P. Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy. Curr Opin Mol Ther 2008; 10: 471-8.
67. Biffi A, Cesani M. Human hematopoietic stem cells in gene therapy: pre-clinical and clinical issues. Curr Gene Ther 2008; 8: 135-46.
68. Seifert MF, Marks SC, Jr. Congenitally osteosclerotic (oc/oc) mice are resistant to cure by transplantation of bone marrow or spleen cells from normal littermates. Tissue Cell 1987; 19: 29-37.
69. Johansson M, Jansson L, Ehinger M, et al. Neonatal hematopoietic stem cell transplantation cures oc/oc mice from osteopetrosis. Exp Hematol 2006; 34: 242-9.
70. Steward CG, Blair A, Moppett J, et al. High peripheral blood progenitor cell counts enable autologous backup before stem cell transplantation for malignant infantile osteopetrosis. Biol Blood Marrow Transplant 2005; 11: 115-21.
71. Kollet O, Dar A, Shivtiel S, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006; 12: 657-64.
72. Wakkach A, Mansour A, Dacquin R, et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 2008; 112: 5074-83.
73. Johansson MK, de Vries TJ, Schoenmaker T, et al. Hematopoietic stem cell targeted neonatal gene therapy reverses lethally progressive osteopetrosis in oc/oc mice. Blood 2007; 109: 5178-85.
74. Askmyr M, Holmberg J, Flores C, et al. Low-dose busulphan conditioning and neonatal stem cell transplantation preserves vision and restores hematopoiesis in severe murine osteopetrosis. Exp Hematol 2009; 37: 302-8.
75. Lindemann C, Schilz AJ, Emons B, et al. Down-regulation of retroviral transgene expression during differentiation of progenitorderived dendritic cells. Exp Hematol 2002; 30: 150-7.
76. Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-53.
77. Modlich U, Kustikova OS, Schmidt M, et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005; 105: 4235-46.
78. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-96.
79. Beranger GE, Momier D, Guigonis JM, et al. Differential binding of poly(ADP-Ribose) polymerase-1 and JunD/Fra2 accounts for RANKL-induced Tcirg1 gene expression during osteoclastogenesis. J Bone Miner Res 2007; 22: 975-83.
80. Beranger GE, Momier D, Rochet N, et al. RANKL treatment releases the negative regulation of the poly(ADP-ribose) polymerase-1 on Tcirg1 gene expression during osteoclastogenesis. J Bone Miner Res 2006; 21: 1757-69.
81. Reddy SV, Hundley JE, Windle JJ, et al. Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter. J Bone Miner Res 1995; 10: 601-6.
82. Li YP, Chen W. Characterization of mouse cathepsin K gene, the gene promoter, and the gene expression. J Bone Miner Res 1999; 14: 487-99.
83. Munaut C, Salonurmi T, Kontusaari S, et al. Murine matrix metalloproteinase 9 gene. 5′-upstream region contains cis-acting elements for expression in osteoclasts and migrating keratinocytes in transgenic mice. J Biol Chem 1999; 274: 5588-96.
84. Roach J, Choi SJ, Schaub RL, et al. Further characterization of the murine collagenase (type IVB) gene promoter and analysis of mRNA expression in murine tissues. Gene 1998; 208: 117-22.
85. Zychlinski D, Schambach A, Modlich U, et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-25.
86. Moreno-Carranza B, Gentsch M, Stein S, et al. Transgene optimization significantly improves SIN vector titers, gp91(phox) expression and reconstitution of superoxide production in X-CGD cells. Gene Ther 2009; 16: 111-8.
87. Christopherson KW, 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305: 1000-3.
88. Tian C, Bagley J, Forman D, Iacomini J. Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther 2006; 13: 652-8.
89. Villa A, Pangrazio A, Caldana E, et al. Prognostic potential of precise molecular diagnosis of Autosomal Recessive Osteopetrosis with respect to the outcome of bone marrow transplantation. Cytotechnology 2008; 58: 57-62.